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Abstract
Enteric glial cells (EGC) actively mediate acute and chronic inflammation in the gut; EGC proliferate and release
neurotrophins, growth factors, and pro-inflammatory cytokines which, in turn, may amplify the immune response,
representing a very important link between the nervous and immune systems in the intestine. Cannabidiol (CBD) is an
interesting compound because of its ability to control reactive gliosis in the CNS, without any unwanted psychotropic
effects. Therefore the rationale of our study was to investigate the effect of CBD on intestinal biopsies from patients with
ulcerative colitis (UC) and from intestinal segments of mice with LPS-induced intestinal inflammation. CBD markedly
counteracted reactive enteric gliosis in LPS-mice trough the massive reduction of astroglial signalling neurotrophin S100B.
Histological, biochemical and immunohistochemical data demonstrated that S100B decrease was associated with a
considerable decrease in mast cell and macrophages in the intestine of LPS-treated mice after CBD treatment. Moreover the
treatment of LPS-mice with CBD reduced TNF-a expression and the presence of cleaved caspase-3. Similar results were
obtained in ex vivo cultured human derived colonic biopsies. In biopsies of UC patients, both during active inflammation
and in remission stimulated with LPS+INF-c, an increased glial cell activation and intestinal damage were evidenced. CBD
reduced the expression of S100B and iNOS proteins in the human biopsies confirming its well documented effect in septic
mice. The activity of CBD is, at least partly, mediated via the selective PPAR-gamma receptor pathway. CBD targets enteric
reactive gliosis, counteracts the inflammatory environment induced by LPS in mice and in human colonic cultures derived
from UC patients. These actions lead to a reduction of intestinal damage mediated by PPARgamma receptor pathway. Our
results therefore indicate that CBD indeed unravels a new therapeutic strategy to treat inflammatory bowel diseases.
Citation: De Filippis D, Esposito G, Cirillo C, Cipriano M, De Winter BY, et al. (2011) Cannabidiol Reduces Intestinal Inflammation through the Control of
Neuroimmune Axis. PLoS ONE 6(12): e28159. doi:10.1371/journal.pone.0028159
Editor: Silvana Gaetani, Sapienza University of Rome, Italy
Received June 28, 2011; Accepted November 2, 2011; Published December 6, 2011
Copyright:  2011 De Filippis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: iuvone@unina.it
. These authors equally contributed to the work.
Introduction
Despite the ancient assumption that enteric glial cells (EGC)
may serve as a mere mechanical support for enteric neurons,
nowadays the knowledge on these cells is consistently expanded.
EGC play a fundamental role in the maintenance of gut
homeostasis since they assure the correct trophism of vicinal
neurons in the myenteric plexus [1] and actively participate in the
course of intestinal inflammation [2] where they appear as first
defensive line against pathogens [3].
Enteroglial cells share analogue features with glial cells in the
brain. EGC play important functions in the maintenance of the
enteric nervous system (ENS) homeostasis, but they may also
proliferate and be activated in response to injury and inflamma-
tion undergoing reactive gliosis (entero-gliosis), a dynamic process
[4]. Enteric astroglial and microglial cells release neurotrophins,
growth factors and cytokines cross-talking with other infiltrating
immune cells such as macrophages, neutrophils and mast cells
[5,6,7].
Abnormalities in the enteroglial network were described in the
intestinal mucosa of patients with inflammatory bowel diseases
(IBD) [8], measures as the reactive enteric gliosis, i.e. the massive
over-expression and secretion of S100B protein, a cell-specific
astroglial derived signalling molecule [9]. The activation of EGC is
therefore regarded as a general alteration of the whole enteric
nervous system homeostasis. S100B protein, which is released by
enteric glial cells, emerges as a pivotal signal molecule that
extensively participates in the onset and in the progression of the
inflammatory status as it orchestrates a wide range of signal
activation pathways, directly correlated with the severity of gut
degenerative processes [8].
Molecules which may counteract intestinal inflammation
targeting EGC could represent putative novel approaches to
amplify the current pharmacological tools to treat gut inflamma-
tory diseases. In this sense, a huge amount of data produced in the
recent years demonstrated that cannabidiol (CBD) the non-
psychotropic cannabinoid deriving from Cannabis Sativa, appears as
a very promising compound because of its antinflammatory,
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inflammation [10]. It was shown that CBD exerts its pharmaco-
logical activity targeting reactive astroglia and this results in a very
efficient reduction of the neuroinflammatory/neurodegenerative
status both in vitro and in vivo models of neuropathologies [11].
To date, the effect of CBD on enteric gliosis which occurs
during acute and chronic gut inflammation has not yet been
evaluated. Therefore, the present study aims to evaluate: (a) the
effect of CBD on enteroglial-derived S100B protein expression in a
mouse model of acute intestinal inflammation and in rectal
biopsies derived from patients with ulcerative colitis; (b) the
efficacy of CBD to prevent S100B-mediated amplification of
inflammatory/immune response through the involvement of other
immune cells such as macrophages and mast cells; (c) the anti-
apoptotic effect of CBD in course of inflammation.
Moreover, here we aim to identify a specific receptor
responsible for CBD action. Therefore, in the present paper we
investigated the involvement of PPAR-c receptor, since recent
data suggest that PPAR-c activation may underlie some of the
pharmacological effects of CBD. In particular, it was showed that
CBD, causes a time-dependent progressive vasorelaxant effect
similar to that of rosiglitazone, a PPAR-c agonist, and that the
effects of CBD were reversed by the presence of the PPAR-c
antagonist, GW9662 [12,13].
Methods
Cultured human intestinal biopsies
The experimental group comprised 18 subjects (median age 49
years, range 33–65) who underwent colonoscopy for colon cancer
screening and had normal rectal mucosa morphology. Eight
subjects were in good general health without any previous medical
or surgical history; 10 subjects were diagnosed ulcerative colitis
(UC). In each subject 3 rectal mucosal samples were obtained 1) at
onset, at first colonoscopy, 2) before any treatment (acute group)
and 3) at the moment of endoscopically diagnosed remission,
(quiescent group). All the subjects underwent endoscopic biopsy
from the rectum for histological assessment. We utilized an
informed consent that all subjects signed. In this consent we
explained to the subjects that extra biopsies could be made to
perform some research as in this case. Moreover, this study has
been approved to ethical committee of University Federico II –
Naples. Whole mount biopsy specimens were cultured, according
to previous report [5], in Dulbecco Modified Eagle’s Medium
(DMEM) supplemented with 5% Foetal Bovine Serum (FBS),
2 mM glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin
Figure 1. Effect of CBD on glial cell hyperactivation in septic
mice. The intraperitoneal administration of CBD in septic mice
significantly reduced S100B protein expression. Results are expressed
as mean 6 SEM of 3 experiments. ***p,0.001 vs. saline; uuup,0.001 vs.
LPS alone.
doi:10.1371/journal.pone.0028159.g001
Figure 2. Effect of CBD on mast cell activation in septic mice. (A) MC presence in intestinal tissue was evaluated in representative histological
analysis of paraffined tissue stained with Toluidine blue. Fields are representative of 3 separate experiments. Original magnification, 1006.
doi:10.1371/journal.pone.0028159.g002
CBD and Gut Inflammation
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28159at 37uCi n5 %C O 2/95% air. Biopsies were placed in 24-well
plates and, depending upon the experiments, the medium was
replaced with fresh medium and tissue was stimulated for 24 h
with exogenous LPS (10 mg/ml)+INF-c (300 U/mL) alone or in
the presence or absence of CBD (10
28–10
26 M), given to the
tissue 30 minutes before LPS+INF-c stimulus. Rectal biopsies
from patients with UC in acute phase were cultured in the
presence of CBD (10
28–10
26 M) for 24 h. In same experiments
GW9662 10
27 M was given together with CBD 10
26 Mi nU C
biopsies in acute phase.
LPS-induced intestinal inflammation
All procedures received approval from the Medical Ethical
Committee of the University of Antwerp, Belgium (number of the
study is B00-023).
Male Swiss OF1 mice (30–40 g) were fasted from 09.00 AM by
removing food pellets but with free access to tap water. At 4.00
PM the mice were weighed and received the first i.p. injection of
cannabidiol (10 mg/kg), or the cannabidiol vehicle (10% ethanol,
10% Tween 80, 80% saline), Thirty min later, the mice were
divided in a control and LPS group receiving, respectively, an i.p.
injection of vehicle or LPS (E. coli 055:B5; 20 mg/kg). Six hours
after injection of vehicle or LPS, mice received a second i.p.
injection of the drug under study (cannabidiol 10 mg/kg or the
vehicle). All drugs were injected in a volume ratio of 10 ml/g
bodyweight. Eighteen hours after LPS or vehicle injection, mice
were anaesthetized with diethyl ether and killed by exsanguina-
tions [14,15].
Preparation of total extracts
For homogenisation, intestinal tissue was placed in ice-cold lyses
buffer (20 mM HEPES, 100 mM MgCl2, 0.4 M NaCl, 0.5 mM
phenylmethylsulphonylfluoride, 15 mg/ml soybean trypsin inhib-
itor, 3 mg/ml pepstatin A, 2 mg/ml leupeptin, 40 mM benzami-
dine, 1 mM dithiothreitol, 1% Nonidet P40, 20% glycerol) in a
ratio of 0.4 ml per 100 mg of tissue and homogenized at the
highest setting for 2–5 min in Polytron PT300 tissue homogeniser.
Protein concentration was determined using the BioRad protein
assay kit.
Western blot Analysis
Immunoblotting analysis of protein was performed on cytosolic
fraction. Cytosolic extract fraction proteins were mixed with gel
loading buffer (50 mM Tris, 10% SDS, 10% glycerol 2-
mercaptoethanol, 2 mg bromophenol/ml) in a ratio of 1:1, boiled
for 5 min and centrifuged at 10.000 g for 10 min. Protein
concentration was determined and equivalent amounts (50 mg) of
each sample were separated under reducing conditions in 12%
SDS-polyacrylamide minigel. The proteins were transferred onto
nitrocellulose membrane according to the manufacturer’s instruc-
tions (Bio-Rad Laboratories, Hercules, CA, USA). Depending
upon the experiments, the membranes were blocked by incubation
at 4uC overnight in high salt buffer (50 mM Trizma base,
500 mM NaCl, 0.05% Tween-20) containing 5% bovine serum
albumin; they were then incubated for 1 h with specific anti-
MMP9 (1:100 v/v; Neomarkers, Fremont, CA), anti-TNF-a
Figure 3. Effect of CBD on mast cell derived. (A) chymase protein expression, (B) MMP-9 protein expression. Results are expressed as mean 6
SEM of 3 experiments ***p,0.001 vs. saline; uuup,0.001 vs. LPS alone Representative Western blot analysis and relative densitometric analysis. Each
bar in panel B shows the mean 6 SD of 3 experiments. ***p,0.001 vs. saline; uuup,0.001 vs. LPS alone.
doi:10.1371/journal.pone.0028159.g003
Figure 4. Effect of CBD on macrophages activation in septic
mice. Immunohistochemical analysis for MAC3, a know marker of
macrophages presence in inflamed tissue, revealed a reduced number
of macrophages in intestinal tissues of CBD treated mice.
doi:10.1371/journal.pone.0028159.g004
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ABCAM, UK); anti-Chymase (1:500 v/v; Neomarkers, Fremont,
CA), anti-iNOS (1:1000 v/v; BD, Franklin Lakes, NJ USA) and
anti-tubulin (1:1000 v/v, Santacruz, Santa Cruz, CA) primary
antibodies followed by incubation with specific horseradish
peroxidase (HRP)-conjugate secondary antibody (Dako, Golstrup,
DK). The immune complexes were developed using enhanced
chemiluminescence detection reagents (Amersham, Italy) accord-
ing to the manufacturer’s instructions and exposed to Kodak X-
Omat film. The protein bands on X-ray film were scanned and
densitometrically analysed with a GS-700 imaging densitometer
(Bio-Rad Laboratories, CA, USA).
Immunohistochemistry
For MAC3 and cleaved-caspase 3 immunohistochemistry
analysis, intestinal tissue deriving from mice were fixed in buffered
formalin, embedded in paraffin, and cut into 4 mm-thick serial
sections. Sections were stained with the primary MAC3 (1:200 v/
v) or cleaved-caspase 3 (1:100 v/v) antibodies. After three 5-min
washes, the secondary antibody was added and the samples were
incubated at room temperature for 20 min. The streptavidin-HRP
detection system was added and samples were incubated at room
temperature. After three 5-min washes, 50 ml of chromogen was
added and the reaction stopped after 1 min in water.
Histological analysis
Intestinal tissues were fixed in 10% formalin. Thin (0.5 mm)
paraffined section were prepared and stained with toluidine blue
as previously described [16] and then processed for light
microscopy examination. MC counting was performed on five
randomly selected sections using an 6100 objective lens.
Nitrite assay
Nitrite production, the stable metabolites of NO, was measured
in 24 hours-cultured biopsies supernatant. The supernatant
(0.1 mL) was added to an equal amount of Griess reagent (1%
sulphanilamide, 0.1% naphtylendiammine, 2.5% H3PO4) and
allowed at room temperature for 10 min. The absorbance of
constituted chromophore was determined using a UV/visible
spectrophotometer at 550 nm. Nitrite levels were determined
using a sodium nitrite standard curve and expressed as nmol/mg.
Drugs used
NaCl 0.9% (PluruleH, Baxter, Lessines, Belgium), LPS (E. coli
serotype 055:B5, Sigma-Aldrich, St Louis, MO, USA), cannabi-
diol (Tocris Bioscience, Bristol, UK). Cannabidiol was dissolved in
10% ethanol, 10% Tween 80, 80% saline.
Presentation of results and statistical analysis
For the functional in vivo experiments on gastric emptying and
the geometric center, values are shown as mean 6 SEM for n
indicating the number of mice used. For statistical analysis, we
used two-way ANOVA. The first factor concerned the presence or
absence of LPS, the second parameter the drug under study. For
post hoc testing we used a one-way ANOVA followed by a
Bonferroni post hoc test or a non-paired Student’s t-test as
appropriate. P values,0.05 were considered to be significant. All
data were analysed with the SPSS for Windows software (SPSS
Inc., Chicago, IL, USA). For Western blot analysis results were
expressed as the mean 6 SEM of n animals where each value is
the average of responses in duplicate sites. Statistical comparisons
were made by one way-ANOVA followed by Bonferroni’s test for
multiple comparisons. P,0.05 was considered to be significant.
Data were analyzed with GraphPad Instat.
Results
Effect of CBD in LPS- induced enteric glial cell activation
in the mouse intestine
Immunoblotting analysis of the protein S100B, considered a
marker of glial cells since it is exclusively localized in glial cells,
revealed that S100B expression was significantly increased in
intestinal tissues from LPS-treated mice compared to control mice
(Fig. 1). Treatment of control mice with CBD had no effect on
Figure 5. Effect of CBD in LPS-induced intestinal TNF-a
expression in the mouse intestine. Western blot analysis showing
the effect of CBD on LPS induced TNF-a expression. Panel (a) shows
TNF-a protein expression; (b) densitometric analysis of corresponding
bands (optical density). Panel A is representative of n=3 separated
experiments. Each bar in panel B shows the mean 6 SD of 3
experiments. ***p,0.001 vs. saline; uuup,0.001 vs. LPS alone.
doi:10.1371/journal.pone.0028159.g005
Figure 6. Effect of CBD on caspase-3 activation. (A) Immunohis-
tochemical analysis for cleaved-caspase-3 showed a reduced number of
caspase3 positive cells in intestinal tissues of CBD treated mice in
confront to LPS mice.
doi:10.1371/journal.pone.0028159.g006
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treated with CBD, S100B expression was significantly reduced to
control values (Fig. 1).
Effect of CBD in LPS-induced mast cell activation in the
mouse intestine
The mast cell occurrence in intestinal tissue sections stained
with toluidine blue is showed in Fig. 2. The mast cells staining
showed that in mice treated with saline and with CBD alone,
the mast cell number was comparable; however the treatment of
mice with LPS induced a significant increase of mast cell
number as compared to saline-treated animals. In the tissue
sections of LPS-treated mice and receiving CBD treatment a
significant reduction in mast cell number was observed. These
results were paralleled to those obtained with western blot
analysis for both chymase (Fig. 3A) and MMP-9 (Fig. 3B); in fact
the protein expression of those mast cell-derived mediators, were
significantly up-regulated in LPS mice and reduced after CBD
treatment.
Effect of CBD in LPS- induced macrophages activation in
the mouse intestine
In intestinal biopsies from control and CBD-treated mice, a
mild immunoreactivity for MAC-3, a well established marker of
macrophages, was observed, contrarily to the strong and diffuse
MAC3 immunoreactivity present in the intestine of LPS-treated
mice. However, when mice receiving LPS were treated with CBD
MAC3 immunostaining significantly decreased (Fig. 4).
Effect of CBD in LPS-induced intestinal TNF-a expression
in the mouse intestine
Immunoblotting analysis of mouse intestinal homogenates
demonstrated that TNF-a protein expression was significantly
enhanced in mice treated with LPS compared to control mice.
CBD treatment per se did not affect TNF-a expression, but almost
completely reversed the increased levels TNF-a observed in LPS-
treated mice (Fig. 5).
Effect of CBD in LPS- induced apoptosis in the mouse
intestine
Immunohistochemical analysis revealed that the expression of
cleaved-caspase 3, the active form of this pro-apoptotic enzyme,
was weakly expressed in intestinal biopsies from control mice and
control-mice treated with CBD. In contrast, a strong and diffuse
cleaved-caspase 3 immunoreactivity was present in the intestine
of LPS-treated mice. Treatment of LPS-mice with CBD
significantly reduced the immunoreactivity for cleaved-caspase
3 (Fig. 6).
Effect of CBD in rectal biopsies of patients with ulcerative
colitis (UC) in the remission phase
When rectal biopsies from patients with UC in remission phase
were cultured for 24 h at 37uC in the presence of LPS plus
IFN-c, S100B and iNOS protein expression were significantly
increased in comparison with un-stimulated biopsies from UC
patients (Fig. 7A and 7B). Pre-treatment of UC biopsies with
CBD significantly reduced, in a dose-dependent manner LPS plus
Figure 7. Effect of CBD in rectal biopsies of patients with ulcerative colitis (UC) in the remission phase. (A) shows the effect of CBD on
glial activation evaluated as S100B protein expression. Western blot and relative densitometric analysis evidenced that CBD significantly and in a
concentration dependent manner reduced LPS- induced S100B. (B) shows the effect of CBD on LPS + INF-c induced iNOS protein expression and (C)
nitrate production. Results are expressed as mean 6 SEM of 3 experiments ***p,0.001 vs. CTR; up,0.05, uuup,0.001 vs. LPS+INF-c.
doi:10.1371/journal.pone.0028159.g007
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treatment significantly and concentration-dependently prevented
LPS plus INF-c induced nitrite levels, the stable metabolite of
NO (Fig. 7C).
Effect of CBD in rectal biopsies of patients with ulcerative
colitis (UC) in the acute phase
Immunoblotting analysis of un-stimulated rectal biopsies from
UC patients in the acute phase revealed that S100B and iNOS
protein expression were increased. The expression of both S100B
and iNOS proteins was significantly and concentration-depen-
dently reduced in biopsies treated with CBD for 24 h (Fig. 8A and
8B).
In parallel, the administration of CBD to UC biopsies in acute
phase significantly inhibited nitrite production (Fig. 8C).
Effect of CBD and GW9662 in rectal biopsies of patients
with ulcerative colitis (UC) in the acute phase
The administration of GW9662, a potent PPAR-c antagonist,
significantly reversed the effect of CBD on glial cell activation
observed in UC biopsies in acute phase, as showed by the
decreased levels of S100B, a marker of glial cell activation. In
parallel, GW9662 counteracted also the previously showed effects
of CBD on iNOS protein expression and NO production (Fig. 9).
Discussion
In the present study we investigated the effect of CBD, as a
possible modulator of the gut neuro-immune axis, based on its
ability to control both inflammatory response, during intestinal
inflammation, and EGC activation. EGC maintain the integrity of
gut mucosa and act as immuno-competent cells against pathogenic
stimuli [17]. They also may trigger and perpetuate gut
inflammation by the set up of a complex cross talk with other
immune system cell types [18]. More recently, enteroglial
activation, through S100B up-regulation, was described in the
rectal mucosa of patients with UC [8], suggesting that pharma-
cological modulation of glial responses may represent a novel
therapeutic approach for intestinal inflammatory pathologies.
In line with this, we found that the LPS-induced inflammatory
response in mice intestine resulted in an increased expression of
S100B, a protein that is exclusively localized in glial cells [19,20].
Interestingly, pre-treatment with CBD was able to prevent glial
cell hyper-activation in the intestine of LPS mice, as revealed by
the decreased expression of S100B. In agreement with this theory,
we found that the decline of S100B expression after CBD
treatment was paralleled by a decreased presence of inflammatory
cells in the intestine of LPS treated mice. Particularly, treatment
with CBD prevented the LPS-induced increase in the number of
mast cell, as underlined by histological analysis and the
measurement of chymase expression, an enzyme that is selectively
contained in mast cell granules. Our results suggest that, by
controlling mast cells, CBD is able to modulate the immune
response to inflammation. Following activation, mast cells trigger
the recruitment of immune cells, among them neutrophils, to the
site of infection [21,15]. In agreement with this theory, we
demonstrated that CBD also reduced the presence of macrophag-
es, as shown by immuno-histochemistry for MAC3, a key marker
of macrophages. Moreover, CBD reduced the LPS-induced over-
expression of several important mediators such as TNF-a and
Figure 8. Effect of CBD in rectal biopsies of patients with ulcerative colitis (UC) in the acute phase. (A) shows the effect of CBD on glial
activation evaluated as S100B protein expression. Western blot and relative densitometric analysis evidenced that CBD significantly and in a
concentration dependent manner S100B expression in biopsies of UC in acute phase. (B) shows the effect of CBD on iNOS protein expression and (C)
nitrate production. Results are expressed as mean 6 SEM of 3 experiments; up,0.05, uuup,0.001 vs. untreated biopsies.
doi:10.1371/journal.pone.0028159.g008
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damage is associated with an alteration in cytokine levels [22,23]
and an increase of gut epithelial apoptosis [24,25]. This agrees well
with our results showing that the treatment with CBD accounts for
a protection of intestinal damage as revealed by analysis of
caspase-3 activation. Taken together all these results suggest, for
the first time, that CBD, by modulating the glial-immune axis,
regulates the fire up of the inflammatory reaction in the intestine
thereby preventing the detrimental intestinal damage.
The deregulation of the ENS not only takes place in the acute
phase of inflammation but is also considered as a promoter event
of chronic inflammation [26,27]. Therefore, in the second part of
this work we focussed on the effect of CBD in human intestinal
biopsies from patients with ulcerative colitis, a chronic intestinal
inflammatory condition.
Our data evidenced that the administration of CBD in cultured
biopsies of UC patients in remission phase was able to reduce the
expression of S100B. A recent study by Cirillo et al., [8] indicates
that cultured biopsies stimulated with LPS+INF-c represent an
adequate ex vivo model for the study of EGCs involvement during
UC. According to this theory, the pre-treatment of LPS/INF-c
biopsies with CBD significantly prevents the expression of S100B,
and therefore the activation of EGC. The reduced enterogliosis
was accompanied with a lower environment in cultured biopsies,
as revealed by the reduction of iNOS and NO production, two key
markers of the inflammatory status [20].
The effects of CBD were confirmed in a second set of
experiments, in biopsies from UC patients in active phase. The
administration of CBD in cultured biopsies significantly reduced
the expression of S100B and, in parallel, decreased the severity of
intestinal inflammation.
Finally, we intended to better elucidate the mechanism of CBD
action. Although CBD does not directly interact with CB1 or CB2
receptors, in our previously study we demonstrated that CBD
indirectly interacts with cannabinoid receptors through the
modulation of the endocannabinoid system in septic mice [14].
In accordance with the recent literature proposing a direct
interaction of CBD with PPAR-c receptor [12,13], in the present
paper, therefore, we tried to counteract the effect of CBD with a
PPAR-c antagonist. Our results indicate that the administration of
GW9662, a potent PPAR-c antagonist, partially reversed CBD
effects first of all on S100B production and consequently also on
parameters (iNOS and NO) in acute phase of UC. This result is
perfectly in line with the important role played by PPAR-c
receptors during intestinal inflammation [28].
Our results indicate that CBD is a key modulator molecule that
may interfere with the enteroglial-mediated interactions in an
intestinal inflammatory environment. Its activity, markedly
focused on S100B protein downregulation, leads to consequent
reduction of intestinal damage occurring during acute and chronic
intestinal inflammatory status and highlights the importance of
glial cells control during these pathological conditions.
The results of the present study correlate and expand the
findings suggesting CBD as a potent compound that is able to
modulate experimental gut inflammation [29,30]. The exact
cellular signalling pathways responsible for the effect of CBD still
remain unclear, even though, for the first time, we identified
PPAR-c as a key receptor in its action during gut inflammation.
Figure 9. Effect of CBD and GW9662 in rectal biopsies of patients with ulcerative colitis (UC) in the acute phase. (A) shows the effect of
CBD and GW9662 on glial activation evaluated as S100B protein expression. Western blot and relative densitometric analysis evidenced that GW9662
significantly counteracts the effect of CBD on S100B expression in biopsies of UC in acute phase. (B) shows the effect of GW9662 and CBD on iNOS
protein expression and (C) nitrate production. Results are expressed as mean 6 SEM of 3 experiments; uuup,0.001 vs. untreated biopsies; **p,0.05,
***p,0.001 vs CBD.
doi:10.1371/journal.pone.0028159.g009
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inflammation, CBD is able to control the inflammatory scenario
and the subsequent intestinal apoptosis through the restoration of
the altered glia-immune homeostasis. CBD is therefore regarded
as a promising therapeutic agent that modulates the neuro-
immune axis, which can be recognised as a new target in the
treatment of inflammatory bowel disorders.
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